Sionna Therapeutics (NASDAQ:SION) Director Sells $40,050.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 900 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $44.50, for a total value of $40,050.00. Following the completion of the transaction, the director owned 3,595,986 shares in the company, valued at $160,021,377. This represents a 0.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,449.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.60, for a total value of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total value of $4,212,726.82.

Sionna Therapeutics Price Performance

SION traded down $1.84 during trading on Friday, hitting $42.37. 1,954,673 shares of the company traded hands, compared to its average volume of 270,007. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $45.00. The stock’s fifty day moving average is $38.54 and its 200 day moving average is $27.05.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Institutional Investors Weigh In On Sionna Therapeutics

A number of large investors have recently added to or reduced their stakes in SION. Millennium Management LLC lifted its holdings in shares of Sionna Therapeutics by 1,425.5% in the 3rd quarter. Millennium Management LLC now owns 214,085 shares of the company’s stock worth $6,296,000 after acquiring an additional 200,051 shares during the last quarter. Jain Global LLC bought a new stake in shares of Sionna Therapeutics during the 3rd quarter valued at about $250,000. Bank of America Corp DE grew its holdings in shares of Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares during the period. Longaeva Partners L.P. purchased a new stake in Sionna Therapeutics in the third quarter worth $1,807,000. Finally, Squarepoint Ops LLC bought a new position in shares of Sionna Therapeutics in the 3rd quarter worth about $299,000.

Analyst Upgrades and Downgrades

SION has been the topic of several recent research reports. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. BTIG Research began coverage on shares of Sionna Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $50.00 target price on the stock. Jones Trading began coverage on shares of Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 price target for the company. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.